Most Read Articles
Saras Ramiya, 22 hours ago
Mundipharma has launched Betadine® Natural Defense personal care product range in Malaysia in collaboration with Watsons.
18 Apr 2018
In patients with rheumatoid arthritis (RA), temporary cessation of methotrexate (MTX) treatment for 2 weeks following influenza vaccination appears to improve the immunogenicity of the vaccine without increasing RA disease activity, according to a study.
Jairia Dela Cruz, 03 May 2018
Acute coronary syndrome (ACS) patients with diabetes mellitus, as well as high-risk nondiabetic patients, appear to obtain significant cardioprotection from the addition of ezetimibe to simvastatin, and this benefit is achieved without compromising safety, according to an exploratory analysis of data from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Roshini Claire Anthony, 6 days ago

Overweight or obese patients taking lorcaserin as an appetite suppressant may have the added benefit of a reduced risk of incident diabetes, according to results of the CAMELLIA-TIMI 61* trial presented at EASD 2018.

Montelukast plus levocetirizine improves allergic rhinitis outcomes in asthma patients

Jairia Dela Cruz
07 Aug 2018

The fixed-dose combination of montelukast plus levocetirizine produces greater improvements in allergic rhinitis symptoms as compared with montelukast alone in patients with concurrent mild-to-moderate asthma, according to the results of a phase III trial. Moreover, the combination is well tolerated with an acceptable safety profile.

Based on the present data, the investigators believe that the fixed-dose combination of the two widely used therapeutic drugs will provide significantly improved rhinitis outcomes in patients with allergic rhinitis and asthma.

The trial randomized 210 adult patients (mean age 43.32 years; 66.67 percent female; 84.29 percent had mild asthma) to treatment with either montelukast plus levocetirizine (10 and 5 mg/day, respectively; n=116) or montelukast monotherapy (10 mg/day; n=112) for 4 weeks after a 1-week placebo run-in period.

Reductions in mean daytime nasal symptom score, the primary efficacy endpoint, was significantly greater in the combination than in the montelukast-alone group (–0.98 vs –0.81; p=0.045). Patients on montelukast/levocetirizine also exhibited a marked decrease in sneezing (p=0.005), as well as marginal improvements in rhinorrhoea, itching and nasal obstruction (p=0.060–0.387). [Clin Ther 2018;doi:10.1016/j.clinthera.2018.04.021]

However, no significant between-group differences were observed for asthma outcomes, including forced expiratory volume in 1 second (FEV1; p=0.6848), forced vital capacity (FVC; p=0.6632), FEV1/FVC (p=0.9459) and asthma control test score (p=0.3604).

Total and mean daily frequencies of rescue medication use during the treatment period were significantly higher in the combination vs the montelukast group (mean total use, 15.62 vs 8.51; p=0.035; mean daily usage, 0.53 vs 0.29; p=0.039).

Montelukast/levocetirizine was well tolerated, with treatment-emergent adverse events (TEAEs) occurring in 16.67 percent of patients vs 16.36 percent in the monotherapy group. Commonly reported AEs in the combination group included upper respiratory tract infection, nasopharyngitis, gastrointestinal disorder and tonsillitis.

“Allergic rhinitis and asthma have long been regarded and treated as separate disorders,” the investigators noted.

However, evidence shows that the severity of rhinitis is linked to the severity of coexisting asthma, and that rhinitis not only worsens asthma prognosis but also lowers quality of life by limiting daily activities and reducing efficiency at work. This association may be explained by the anatomic, physiological and immunologic mechanisms of the upper and lower airways. [BMC Plum Med 2006;6:S3; Clin Exp Allergy 2005;35:282-287]

“All of this information indicates that rhinitis and asthma are manifestations of either the same or similar inflammatory processes that develop in the common respiratory tract tissue. It is therefore important that rhinitis and asthma not be evaluated as separate disorders, and both [conditions] need to be treated when they coexist,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Saras Ramiya, 22 hours ago
Mundipharma has launched Betadine® Natural Defense personal care product range in Malaysia in collaboration with Watsons.
18 Apr 2018
In patients with rheumatoid arthritis (RA), temporary cessation of methotrexate (MTX) treatment for 2 weeks following influenza vaccination appears to improve the immunogenicity of the vaccine without increasing RA disease activity, according to a study.
Jairia Dela Cruz, 03 May 2018
Acute coronary syndrome (ACS) patients with diabetes mellitus, as well as high-risk nondiabetic patients, appear to obtain significant cardioprotection from the addition of ezetimibe to simvastatin, and this benefit is achieved without compromising safety, according to an exploratory analysis of data from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Roshini Claire Anthony, 6 days ago

Overweight or obese patients taking lorcaserin as an appetite suppressant may have the added benefit of a reduced risk of incident diabetes, according to results of the CAMELLIA-TIMI 61* trial presented at EASD 2018.